In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Biogen stock opened at $137.33 on Thursday. The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a ...

The only other time Biogen stock has spiked was in September 2022, when, alongside Japanese Pharma Eisai, its development partner in the Alzheimer's treatment field, the company shared data from a ...

The firm owned 4,179 shares of the biotechnology company’s stock after acquiring an additional 423 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $639,000 at the ...

The stock's fall snapped a seven-day winning streak.

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ ...

The company generated free cash flow of $722 million in Q4 and $2.7 billion for the year. Biogen issued downside guidance for 2025 with an EPS forecast between $15.25 to $16.25 versus $16.33.

Biogen on Tuesday agreed to pay $165 million upfront for exclusive rights to sell the drug, called zorevunersen, outside the U.S., Canada and Mexico. The company also agreed to split external ...

Deep-pocketed investors have adopted a bullish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Following our analysis of the options activities associated with Biogen, we pivot to a closer look at the company's own performance. With a volume of 1,409,926, the price of BIIB is up 1.32% at ...